Workshop C: Harnessing Digital Biomarkers for Internal Decision-Making in Alzheimer’s & Parkinson’s Disease
Time: 1:30 pm
day: Pre-Conference Workshop Day
Details:
As the FDA moves towards defining digital biomarkers as digital health assessments, wearable technology becomes more refined and digital markers can provide early signs of drug efficacy. Digital biomarkers can support with earlier detection to provide more longitudinal and frequent assessment, but also support internal decision making for biopharma by better predicting drug efficacy.
Look forward to:
- Exploring stride velocity as a newly approved digital marker by the EMA and the direction that regulation is moving in
- Utilizing digital insoles to monitor stride velocity as a marker of motor symptoms for Parkinson’s Disease
- Utilizing passive collections monitoring activity over time from walking, shopping, social engagement and interactions
- Navigating the regulatory route to home testing to improve patient compliance
- Harnessing home EEG devices for measuring sleep and sleep disturbance as a marker of Alzheimer’s Disease
- Using artificial intelligence and machine learning to predict deviation from baseline to establish using digital biomarker
